499 related articles for article (PubMed ID: 23109883)
21. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration.
Johnson JA; Johnson DA; Kraft AD; Calkins MJ; Jakel RJ; Vargas MR; Chen PC
Ann N Y Acad Sci; 2008 Dec; 1147():61-9. PubMed ID: 19076431
[TBL] [Abstract][Full Text] [Related]
22. Dimethyl fumarate improves cognitive deficits in chronic cerebral hypoperfusion rats by alleviating inflammation, oxidative stress, and ferroptosis via NRF2/ARE/NF-κB signal pathway.
Yan N; Xu Z; Qu C; Zhang J
Int Immunopharmacol; 2021 Sep; 98():107844. PubMed ID: 34153667
[TBL] [Abstract][Full Text] [Related]
23. Targeting crosstalk between Nuclear factor (erythroid-derived 2)-like 2 and Nuclear factor kappa beta pathway by Nrf2 activator dimethyl fumarate in epileptogenesis.
Singh N; Vijayanti S; Saha L
Int J Neurosci; 2018 Oct; 128(10):987-994. PubMed ID: 29447051
[TBL] [Abstract][Full Text] [Related]
24. Activation of nuclear factor erythroid 2-related factor 2 cytoprotective signaling by curcumin protect primary spinal cord astrocytes against oxidative toxicity.
Jiang H; Tian X; Guo Y; Duan W; Bu H; Li C
Biol Pharm Bull; 2011; 34(8):1194-7. PubMed ID: 21804205
[TBL] [Abstract][Full Text] [Related]
25. Mode of action and clinical studies with fumarates in multiple sclerosis.
Salmen A; Gold R
Exp Neurol; 2014 Dec; 262 Pt A():52-6. PubMed ID: 24568735
[TBL] [Abstract][Full Text] [Related]
26. The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases.
Joshi G; Johnson JA
Recent Pat CNS Drug Discov; 2012 Dec; 7(3):218-29. PubMed ID: 22742419
[TBL] [Abstract][Full Text] [Related]
27. Activation of Nrf2/Keap1 pathway by oral Dimethylfumarate administration alleviates oxidative stress and age-associated infertility might be delayed in the mouse ovary.
Akino N; Wada-Hiraike O; Isono W; Terao H; Honjo H; Miyamoto Y; Tanikawa M; Sone K; Hirano M; Harada M; Hirata T; Hirota Y; Koga K; Oda K; Fujii T; Osuga Y
Reprod Biol Endocrinol; 2019 Feb; 17(1):23. PubMed ID: 30760288
[TBL] [Abstract][Full Text] [Related]
28. Modulation of mitochondrial dysfunction in neurodegenerative diseases via activation of nuclear factor erythroid-2-related factor 2 by food-derived compounds.
Denzer I; Münch G; Friedland K
Pharmacol Res; 2016 Jan; 103():80-94. PubMed ID: 26626189
[TBL] [Abstract][Full Text] [Related]
29. Antioxidant and Anti-inflammatory Effect of Nrf2 Inducer Dimethyl Fumarate in Neurodegenerative Diseases.
Scuderi SA; Ardizzone A; Paterniti I; Esposito E; Campolo M
Antioxidants (Basel); 2020 Jul; 9(7):. PubMed ID: 32708926
[TBL] [Abstract][Full Text] [Related]
30. Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies.
Linker RA; Lee DH; Stangel M; Gold R
Expert Rev Neurother; 2008 Nov; 8(11):1683-90. PubMed ID: 18986239
[TBL] [Abstract][Full Text] [Related]
31. BG-12 in multiple sclerosis.
Phillips JT; Fox RJ
Semin Neurol; 2013 Feb; 33(1):56-65. PubMed ID: 23709213
[TBL] [Abstract][Full Text] [Related]
32. Dimethyl fumarate for multiple sclerosis.
Papadopoulou A; D'Souza M; Kappos L; Yaldizli O
Expert Opin Investig Drugs; 2010 Dec; 19(12):1603-12. PubMed ID: 21067468
[TBL] [Abstract][Full Text] [Related]
33. An Overview of the Nrf2/ARE Pathway and Its Role in Neurodegenerative Diseases.
Zgorzynska E; Dziedzic B; Walczewska A
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502501
[TBL] [Abstract][Full Text] [Related]
34. Dimethyl Fumarate is a Potential Therapeutic Option for Alzheimer's Disease.
Sun X; Suo X; Xia X; Yu C; Dou Y
J Alzheimers Dis; 2022; 85(1):443-456. PubMed ID: 34842188
[TBL] [Abstract][Full Text] [Related]
35. Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion.
Cho H; Hartsock MJ; Xu Z; He M; Duh EJ
J Neuroinflammation; 2015 Dec; 12():239. PubMed ID: 26689280
[TBL] [Abstract][Full Text] [Related]
36. Fumaric acid esters stimulate astrocytic VEGF expression through HIF-1α and Nrf2.
Wiesner D; Merdian I; Lewerenz J; Ludolph AC; Dupuis L; Witting A
PLoS One; 2013; 8(10):e76670. PubMed ID: 24098549
[TBL] [Abstract][Full Text] [Related]
37. Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.
Johnson DA; Johnson JA
Free Radic Biol Med; 2015 Nov; 88(Pt B):253-267. PubMed ID: 26281945
[TBL] [Abstract][Full Text] [Related]
38. Recent progress and applications of small molecule inhibitors of Keap1-Nrf2 axis for neurodegenerative diseases.
Wang J; Cao Y; Lu Y; Zhu H; Zhang J; Che J; Zhuang R; Shao J
Eur J Med Chem; 2024 Jan; 264():115998. PubMed ID: 38043492
[TBL] [Abstract][Full Text] [Related]
39. K(ATP) channel opener diazoxide prevents neurodegeneration: a new mechanism of action via antioxidative pathway activation.
Virgili N; Mancera P; Wappenhans B; Sorrosal G; Biber K; Pugliese M; Espinosa-Parrilla JF
PLoS One; 2013; 8(9):e75189. PubMed ID: 24040400
[TBL] [Abstract][Full Text] [Related]
40. Oxidative Stress and the Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Pathway in Multiple Sclerosis: Focus on Certain Exogenous and Endogenous Nrf2 Activators and Therapeutic Plasma Exchange Modulation.
Tonev D; Momchilova A
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
